Copy number variations (CNVs) are genomic alterations that result in an abnormal number of copies of one or more genes. Structural genomic rearrangements such as duplications, deletions, translocations, and inversions can cause CNVs.
Like single-nucleotide polymorphisms (SNPs), certain CNVs have been associated with disease susceptibility. Illumina offers a variety of array and next-generation sequencing (NGS) solutions for high-resolution copy number analysis.
Genome-wide genotyping arrays are commonly used to detect genetic variants, including CNVs that contribute to diseases and phenotypes. Array-based approaches for copy number analysis offer reliable, efficient methods for large-scale analysis.
Researchers can process multiple samples on a single microarray for broad surveys of genomic structural variation, and accurately profile chromosomal aberrations such as amplifications, deletions, rearrangements, and copy-neutral loss of heterozygosity.
Illumina offers both human and non-human genotyping arrays for CNV analysis. Illumina scientists strategically select the markers on the arrays to provide maximum genome coverage for optimal copy number analysis.
Arrays for cytogenomic research, which are specifically validated for CNV analysis as part of the manufacturing process.Learn More
Unbiased, non-targeted approach for human variant detection, providing high coverage across the human genome.Learn More
Comprehensive suite of array-based kits for genotyping non-human species such as crops, livestock, and model organisms.Learn More
Design custom or semi-custom arrays for any species, with convenient online tools and Illumina expert assistance.Learn More
While efficient for large CNV detection, genotyping arrays are less sensitive for detecting CNVs smaller than 50 kilobases. By providing a base-by-base view of the genome, NGS detects small or novel copy number variants that arrays often miss.
NGS can also map the exact location of a CNV. The high resolution of sequencing complements the high throughput of arrays, enabling a comprehensive view of the genome.
Identify the greatest number of variants and sequence challenging regions.View Product
Efficiently interrogate samples with limited available DNA, with high coverage quality and reduced bias.View Product
Analyze whole-genome sequencing data using fast, accurate Isaac algorithms for alignment and calling of variants, including CNVs.View App
The DRAGEN Bio-IT Platform provides accurate, ultra-rapid copy number variation analysis for broad surveys of genomic structurial variation.Learn More
Copy number variation often alters gene expression. Targeted RNA sequencing (RNA-Seq) is an unbiased approach for analyzing and quantifying transcripts of interest. RNA-Seq can capture subtle gene expression changes, measure allele-specific expression, and detect fusion genes. By characterizing the downstream effects of variants, researchers can better understand the molecular mechanisms of disease. Learn more about targeted RNA-Seq.
Genomic luminaries Drs. Marc Lalande and Kamran Shazand establish the Genomics InstituteRead Article
A computer scientist transforms the world of biology by making bioinformatics tools available to all.Read Interview
Illumina sequencing and software analysis are best in class for accuracyRead Article
Illumina offers microarrays designed to detect chromosome aberrations and provide accurate cytogenomic data. NGS may be used to confirm copy number variants detected by arrays. Learn more about cytogenomics.
Sequencing- and array-based technologies offer complementary approaches for studying chromosomal rearrangements, CNVs, and other abnormalities in cancer samples. Learn more about cancer chromosomal abnormality studies.
Array and NGS solutions can help researchers identify causative variants, including CNVs, associated with complex diseases. Learn more about complex disease research.
Illumina offers solutions for rapid preimplantation genetic diagnosis (PGD) of single-gene disorders and balanced chromosomal translocations in IVF embryos. Learn more about PGD.